Remove 2023 Remove Healthcare Provider Remove Pharmaceutical manufacturing
article thumbnail

Top-10 ways for Pharma to leverage AI according to…AI

Impetus Digital

Looking back at 2023 , AI for drug discovery saw both wins and losses. Manufacturing Optimization While the manufacturing industry lags behind others in terms of AI uptake, there is no shortage of potential ways to leverage this technology. In 2022, the AI-fuelled pipeline reportedly expanded at an annual rate of almost 40%.

Pharma 94
article thumbnail

Trends in Virtual Collaboration

Impetus Digital

With the end of the year quickly approaching, you will likely see multiple articles on the key trends of 2023 and predictions for 2024 start popping up. A version of this article was previously published in the Journal of mHealth. Many of these will discuss the expanding role and capabilities of AI and machine learning in the Pharma space.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Diversity and inclusion in oncology clinical trials

Clarify Health

The American Medical Association’s 2021-2023 Organizational Strategic Plan to Embed Racial Justice and Advance Health Equity In February 2021, the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research issued new recommendations in five specific areas to broaden oncology trial eligibility criteria to include minorities.

article thumbnail

Getting ahead of regulatory changes around PFAS in pharmaceutical packaging

Clarivate

Nitrosamines have garnered significant attention from the pharmaceutical industry due to their detection in commonly prescribed medications for conditions like type 2 diabetes, high blood pressure, and heartburn. [1] Manufacturers, healthcare providers, and consumers alike face the need to quickly adapt.

article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

Pharmaceutical manufacturers have submitted Citizen Petitions raising safety or efficacy concerns about proposed competing generic and biosimilar products, and such submissions often delay FDA approval of the proposed products while the FDA resolves the pending petitions.